BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Sanofi Genzyme’s Bill Sibold Champions Diversity, Community Responsibility

  Bill Sibold, executive vice president and head of Sanofi Genzyme, is passionate about fomenting programs that increase the diversity of the workforce in his company and the pharmaceutical industry as a whole.

  November 19, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Research Roundup: Healthcare Workers Highest Risk for COVID-19 and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  November 19, 2020

   · 

  5 min read

   · 

  Mark Terry
• 

  Biotech Beach

  In Fight Against Blood Cancer, Imago Doubles Down with $80 Million Series C

  Funding raised will be used to take lead candidate into Phase III clinical trials.

  November 19, 2020

   · 

  2 min read

   · 

  Kate Goodwin
• 

  BioCapital

  COVID-19 Vaccine Rollout Timeline: Possibly Beginning Distribution in December

  The looming question is: when will the public be able to start getting the vaccines?

  November 19, 2020

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol

  Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, SVP of finance.

  November 19, 2020

   · 

  3 min read

   · 

  Gail Dutton
• 

  Deals

  Olema Oncology Prices IPO at $19 Per Share, Expects Gross Proceeds of $209 Million

  In the IPO announcement, Olema Oncology notes it has granted the underwriters a 30-day option to buy up to 1,650,000 more common stock shares at the IPO price.

  November 19, 2020

   · 

  3 min read

   · 

  Brandon May
• 

  FDA

  FDA Grants EUA to Combination of Olumiant and Remdesivir in Hospitalized COVID-19 Patients

  The EUA for the combination of Olumiant and Remdesivir marks the first combination for COVID-19 greenlit in the U.S.

  November 19, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  AstraZeneca and Oxford’s COVID-19 Vaccine Shows Promise in Elderly Adults

  AstraZeneca and the University of Oxford published Phase II clinical trial results for their COVID-19 vaccine in The Lancet. The data shows the vaccine is safe and offers a similar immune response in all adults.

  November 19, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Details Surrounding Nation’s COVID-19 Response in Limbo as Election Results Remain Unresolved

  With limited doses currently available, the logistics of inoculation are in the works and will certainly require guidance from the outgoing and incoming administrations of Donald Trump and Joe Biden, respectively.

  November 19, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  New Understanding of eTreg Cells Signals Hope for Inflammatory Diseases

  Scientists at St. Jude Children’s Research Hospital have revealed insight into the metabolic signaling pathways influencing eTreg cells that could lead to new therapies for inflammatory diseases and related disorders.

  November 19, 2020

   · 

  2 min read

   · 

  Heather McKenzie